A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
9 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced bone and soft tissue tumors.
Age 16 to 75 years, diagnosed with soft tissue sarcoma or bone neoplasms clearly... [+9]
Have had any serious adverse reactions associated with immunotherapy and have no... [+10]